Figure 3.
Molecular events responsible to MPN onset and evolution. This image summarizes the molecular processes and pathways involved in MPN onset and leukemic evolution described in the main text. Abbreviations: JAK2: Janus Kinase 2; CALR: Calreticulin; TPO-R: Thrombopoietin Receptor; STAT: Signal Transducer and Transcription Activator; PRC2: Polycomb Repressive Complex 2; ASXL1: Additional Sex Combs Like 1; EZH2: Enhancer of Zeste Homolog 2; EED: Polycomb protein EED; SUZ12: Polycomb protein SUZ12; RBBP4/7: Histone-binding protein RBBP4/7; Ac: Acetylation; Me3: three-methylation; H3K27: Histone 3 Lysin 27; DNMT3A: DNA methyltransferase 3 α; TET2: Ten-Eleven-Translocation 2; IDH1/2: Isocitrate Dehydrogenases 1/2; ISO: Isocitrato; α-KG: α-ketoglutarate; 2-HG: 2-Hidroxyglutarate; p53: Tumor Protein 53; SRSF2: Serine/Arginine Rich Splicing Factor 2; SF3B1: Splicing factor 3B subunit 1; U2AF1: Splicing factor U2AF 35 kDa subunit; U2AF1: U2 small nuclear ribonucleoprotein auxiliary factor 35 kDa subunit-related protein 2; RUNX1: Runt-related transcription factor 1; SETBP1: SET binding protein 1; FLT3: FMS-like tyrosine kinase 3; SHP2: SH2 containing protein tyrosine phosphatase-2; Ras: Rat sarcoma virus; Raf: RAF proto-oncogene serine/threonine-protein kinase; MEK: Mitogen-activated protein kinase kinase; ERK: extracellular signal-regulated kinase; STAG2: Stromal Antigen 2; NPM1: Nucleophosmin; PU.1: Transcription factor PU.1. Created with BioRender.com.